Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H21ClN2S |
| Molecular Weight | 344.901 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(Cl)C=C4
InChI
InChIKey=XRYLGRGAWQSVQW-UHFFFAOYSA-N
InChI=1S/C19H21ClN2S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,13,17H,8-12H2,1H3
| Molecular Formula | C19H21ClN2S |
| Molecular Weight | 344.901 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Clorotepine (aka octoclothepin or octoclothepine) is an antipsychotic from the tricyclic group derived from perathiepin. It was originally developed in 1965 and marketed in the Czech Republic by Spofa in or around 1971 for the treatment of schizophrenic psychosis. Clorotepine has a high affinity for the dopamine (D1, D2, D3, D4), receptors the serotonin 5-HT (2A, 2B, 2C, 6, 7) receptors, the alpha-adrenergic receptors (1A, 1B, 1D), and the histamine H1 receptors. In most instances, it acts as an antagonist (or inverse agonist). Clorotepine will also block the reuptake of norepinephrine by inhibiting the norepinephrine transporter.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
0.57 nM [IC50] | ||
Target ID: P35348|||B0ZBD9|||Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
0.18 nM [IC50] | ||
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
2.2 nM [IC50] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1676758 |
2.4 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Clotepin Approved UseUnknown |
|||
| Primary | Clotepin Approved UseUnknown |
|||
| Primary | Clotepin Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. | 2001 |
|
| Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists. | 1991-07 |
|
| On acute effects of some drugs on the higher nervous activity in man (the acoustic analyser). Clorotepin (0.5 mg and 1.0 mg), pemoline (100 mg). Part LI. | 1985 |
|
| On acute effects of some drugs on the higher nervous activity in man. Clorotepin (2 mg), its (+)-enantiomer (2 mg) and (-)-enantiomer (2 mg). | 1980 |
|
| Further clinical experiences with optical isomers of the L and D clorothepin. | 1979 |
|
| Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings. | 1978-12 |
|
| Clinical experience with octoclothepine in chronic mental patients. | 1972 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6231812
Clorotepin is provided in doses up to 2 mg.
Route of Administration:
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:06 GMT 2025
by
admin
on
Mon Mar 31 18:30:06 GMT 2025
|
| Record UNII |
E65W20MU7A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1238
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
E65W20MU7A
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
Clorotepine
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
3423
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
100000084010
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
DTXSID7048451
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
13448-22-1
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
CHEMBL64249
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
C100288
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
C77572
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
3912
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY | |||
|
SUB06765MIG
Created by
admin on Mon Mar 31 18:30:06 GMT 2025 , Edited by admin on Mon Mar 31 18:30:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |